ASCO President-Elect Julie Vose, MD, MBA

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.

Lung Cancer

David E. Gerber, MD, and James L. Mulshine, MD

David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).

Breast Cancer

Jame Abraham, MD

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).

Skin Cancer

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Leukemia

Lymphoma

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

The Molecular Watchman Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers

Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases

Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia

Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis

Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study